Drug intelligence / Profile preview

willardiine

Development stage
Unknown
Modality
Small Molecules
01

Overview

Willardiine is a naturally occurring amino acid derivative isolated from the seeds of Acacia willariana. It acts as a partial agonist at ionotropic glutamate receptors—specifically the non-NMDA subtypes AMPA and kainate receptors. These receptors are found at excitatory synapses in the central nervous system and mediate fast synaptic transmission by binding glutamate or structurally similar ligands such as willardiine. Activation of these receptors by willardiine leads to an influx of positive ions into neurons and subsequent neural depolarization. Willardiine has been primarily used as a research tool to study receptor structure and function; it is not approved for therapeutic use in any indication[1][2]. Only the (S)-isomer binds effectively to AMPA/kainate receptors[2]. Overactivation can cause neurotoxicity, but at typical research concentrations, toxicity is low[2].

Other names
beta-(2,4-dihydroxypyrimidin-1-yl)alanine3-(1-uracyl)-L-alanine(S)-willardiineL-willardiine
02

Targets

AMPAR (AMPA receptor)Kainate-type ionotropic glutamate receptor

Beyond the preview

Go deeper on willardiine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on willardiine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call